Placebo

A placebo is an inert or inactive treatment that is designed to resemble the experimental intervention in appearance, administration, and sensory characteristics but contains no active therapeutic ingredient. In clinical trials, placebos serve as controls, enabling researchers to distinguish the specific effects of the intervention from the nonspecific effects of receiving treatment.

The placebo is a foundational concept in clinical trial methodology because it addresses one of the most fundamental challenges in evaluating treatments: separating the true pharmacological or therapeutic effect of an intervention from the wide range of nonspecific effects that accompany any treatment. When patients receive a treatment, they may improve for reasons unrelated to the treatment's active mechanism: the natural course of the disease, regression to the mean, the therapeutic relationship with the clinician, the ritual of taking a pill, and the psychological expectation of improvement all contribute to observed outcomes. Without a concurrent control group, all of these effects are conflated with the treatment effect, potentially leading researchers to conclude that an ineffective treatment works; a no treatment control accounts for the natural course and regression to the mean but still leaves the effects of expectation and the treatment ritual mixed in. The placebo controlled trial, by giving both groups the same nonspecific experience while varying only the active ingredient, isolates the specific treatment effect, provided the blinding holds.

Placebos are designed to be indistinguishable from the active treatment. For an oral medication, the placebo is a pill or capsule that looks, tastes, and feels identical to the study drug but contains no active compound (typically lactose, starch, or other inert fillers). For an injectable drug, the placebo is a saline or other inactive solution administered with the same type of syringe and by the same route. For medical devices, sham procedures may serve as placebos (such as a sham arthroscopic surgery where small incisions are made but no therapeutic procedure is performed).

The improvement observed in patients who receive a placebo is called the placebo response. It includes the natural course of the condition and regression to the mean as well as the placebo effect itself: the part of the improvement caused by receiving the placebo, with the expectations and treatment context that come with it. The placebo effect is real (patients actually experience reduced pain, improved mood, or other benefits) and is mediated by neurobiological mechanisms including endorphin release, dopamine signaling, and expectation driven changes in neural activity. The magnitude of the placebo effect varies by condition (it is typically larger for subjective outcomes such as pain, nausea, and depression than for objective outcomes such as tumor size or viral load), by the characteristics of the placebo (some studies have found larger effects with injections than with pills, and with placebos presented as more expensive), and by the clinical context. In blinded trials, participants know they may receive a placebo but not whether they do. Some small trials have instead given open label placebos, telling participants that the pill is inert, and reported improvements in self reported symptoms in conditions such as irritable bowel syndrome and chronic low back pain; these trials are mostly small and cannot blind participants, so the evidence remains uncertain.

The nocebo effect is the placebo effect's counterpart: negative expectations produce negative outcomes. Patients who are warned about potential side effects of a treatment (or placebo) are more likely to experience those side effects, a phenomenon with important implications for informed consent discussions in clinical trials.

Ethical considerations surround placebo use. The Declaration of Helsinki, most recently revised in October 2024, requires a new intervention to be tested against the best proven intervention, except when no proven intervention exists, or when compelling and scientifically sound methodological reasons make a placebo necessary and the participants who receive it will not be subject to additional risks of serious or irreversible harm as a result of not receiving the best proven intervention; it adds that extreme care must be taken to avoid abuse of this option. Active controlled trials (comparing the experimental treatment to the current standard of care), or add on designs in which every participant receives the standard treatment plus either the new treatment or a placebo, are the alternatives when withholding effective treatment would expose participants to additional risks of serious or irreversible harm.

Use a placebo control when no proven effective treatment exists for the condition, when the research question specifically requires distinguishing the drug's effect from the placebo effect, or when regulatory agencies require placebo controlled data for approval. When an effective treatment exists and withholding it would expose participants to additional risks of serious or irreversible harm, use an active comparator or an add on design instead. Obtain ethics committee approval before using placebos, explain in the informed consent process that participants may receive a placebo, and design the study so that participants' welfare is not compromised.

A common mistake is using a placebo control when an effective standard treatment exists and withholding it would expose participants to additional risks of serious or irreversible harm, violating ethical principles. Another error is assuming that a placebo controlled trial automatically proves the clinical value of a treatment; a drug that beats placebo may still be inferior to existing treatments. The distinction between "better than nothing" and "better than what we already have" is critical. Poorly manufactured placebos that do not match the active treatment in appearance, taste, or other characteristics compromise blinding and introduce bias. Finally, researchers sometimes describe a no treatment control as a placebo control, conflating the absence of treatment with the administration of an inert treatment, which have different effects on participant expectations and behavior.

A Phase III trial evaluates a new oral medication for chronic migraine prophylaxis. Participants receive either the active drug (one tablet daily) or a matching placebo (identical in size, shape, color, and coating). After 12 weeks, migraine frequency decreases by 4.2 days per month in the drug group and by 2.1 days per month in the placebo group. The 2.1 day reduction in the placebo group reflects the combination of natural disease fluctuation, regression to the mean, and the placebo effect. The difference between the groups, 2.1 days per month, estimates the treatment effect attributable to the drug's pharmacological action. This distinction, made possible by the placebo control, would be invisible in an uncontrolled study.